South Korea
· Delayed Price · Currency is KRW ViGenCell Statistics
Total Valuation
ViGenCell has a market cap or net worth of KRW 49.80 billion. The enterprise value is 9.49 billion.
| Market Cap | 49.80B |
| Enterprise Value | 9.49B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ViGenCell has 19.26 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 19.26M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 7.12% |
| Owned by Institutions (%) | 4.05% |
| Float | 13.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.62 |
| EV / Sales | 170.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.66 |
Financial Position
The company has a current ratio of 5.98, with a Debt / Equity ratio of 0.13.
| Current Ratio | 5.98 |
| Quick Ratio | 5.94 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -47.92 |
Financial Efficiency
Return on equity (ROE) is -22.17% and return on invested capital (ROIC) is -13.94%.
| Return on Equity (ROE) | -22.17% |
| Return on Assets (ROA) | -13.55% |
| Return on Capital (ROIC) | -13.94% |
| Revenue Per Employee | 853,846 |
| Profits Per Employee | -236.28M |
| Employee Count | 65 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -42.29% |
| 50-Day Moving Average | 3,028.30 |
| 200-Day Moving Average | 3,962.88 |
| Relative Strength Index (RSI) | 39.22 |
| Average Volume (20 Days) | 477,934 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ViGenCell had revenue of KRW 55.50 million and -15.36 billion in losses. Loss per share was -799.80.
| Revenue | 55.50M |
| Gross Profit | 134.87M |
| Operating Income | -17.15B |
| Pretax Income | -15.36B |
| Net Income | -15.36B |
| EBITDA | -13.26B |
| EBIT | -17.15B |
| Loss Per Share | -799.80 |
Balance Sheet
The company has 48.07 billion in cash and 7.76 billion in debt, giving a net cash position of 40.31 billion or 2,092.48 per share.
| Cash & Cash Equivalents | 48.07B |
| Total Debt | 7.76B |
| Net Cash | 40.31B |
| Net Cash Per Share | 2,092.48 |
| Equity (Book Value) | 61.36B |
| Book Value Per Share | 3,185.06 |
| Working Capital | 40.62B |
Cash Flow
In the last 12 months, operating cash flow was -14.30 billion and capital expenditures -112.41 million, giving a free cash flow of -14.41 billion.
| Operating Cash Flow | -14.30B |
| Capital Expenditures | -112.41M |
| Free Cash Flow | -14.41B |
| FCF Per Share | -748.14 |
Margins
| Gross Margin | 243.02% |
| Operating Margin | -30,899.42% |
| Pretax Margin | -27,672.42% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ViGenCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | -30.94% |
| FCF Yield | -28.94% |
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jun 8, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
ViGenCell has an Altman Z-Score of 3.53.
| Altman Z-Score | 3.53 |
| Piotroski F-Score | n/a |